Johnson & Johnson (NYSE:JNJ) Shares Purchased by Cozad Asset Management Inc.

Posted by Defense World Staff on May 13th, 2023

Cozad Asset Management Inc. boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 9.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,701 shares of the company’s stock after buying an additional 1,365 shares during the quarter. Cozad Asset Management Inc.’s holdings in Johnson & Johnson were worth $2,774,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Ieq Capital LLC raised its stake in shares of Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after purchasing an additional 6,154 shares in the last quarter. Duality Advisers LP bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $4,342,000. Modera Wealth Management LLC grew its position in shares of Johnson & Johnson by 18.0% during the 4th quarter. Modera Wealth Management LLC now owns 44,189 shares of the company’s stock valued at $7,806,000 after buying an additional 6,738 shares during the last quarter. RFG Advisory LLC grew its position in shares of Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after buying an additional 594 shares during the last quarter. Finally, Willis Investment Counsel grew its position in shares of Johnson & Johnson by 0.4% during the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after buying an additional 1,358 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Buying and Selling

In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have commented on JNJ. SVB Leerink decreased their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. UBS Group initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Finally, Piper Sandler cut their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $160.78 on Friday. The company has a market cap of $417.82 billion, a PE ratio of 33.64, a price-to-earnings-growth ratio of 2.77 and a beta of 0.53. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a fifty day moving average price of $159.10 and a two-hundred day moving average price of $166.76. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter last year, the company posted $2.67 EPS. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.96%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.